The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib study of BI 836880 (VEGF/Ang2 inhibitor) plus ezabenlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with advanced hepatocellular carcinoma (HCC).
 
Tim Meyer
Consulting or Advisory Role - Bayer; Beigene; BTG; Eisai; Ipsen; MSD; Roche
Research Funding - Bayer (Inst); BTG (Inst); Ipsen (Inst)
 
Evgeny Ledin
Research Funding - Boehringer Ingelheim; Boehringer Ingelheim (Inst)
 
Dong-Wan Kim
Research Funding - Alpha Biopharma (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); BridgeBio Pharma (Inst); Chong Kun Dang Pharmaceutical (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Hanmi (Inst); Janssen (Inst); Merus (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst); TP Therapeutics (Inst); Xcovery (Inst); Yuhan (Inst)
Travel, Accommodations, Expenses - Amgen; Daiichi Sankyo
 
François Ghiringhelli
Honoraria - roche
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Roche/Genentech; Roche/Genentech
 
Piotr Serwatowski
No Relationships to Disclose
 
Mark Voskoboynik
Consulting or Advisory Role - AstraZeneca
 
Harald Timotheus Landsteiner
Employment - Boehringer Ingelheim
 
Victoria Chen
Employment - Boehringer Ingelheim
 
Girish Jayadeva
Employment - Boehringer Ingelheim
 
Teresa Macarulla
Consulting or Advisory Role - Ability Pharma; Advance Medical; Aptitude Health; AstraZeneca; Basilea; Baxter; BioLineRX; Celgene; Eisai; Genzyme; Incyte; Ipsen; Lilly; Medscape; Menarini; MSD; Novocure; Paraxel; PPD; Prime Oncology; QED Therapeutics; Roche; Sanofi/Aventis; SERVIER; Swedish Orphan Biovitrum; Zymeworks
Research Funding - Agios (Inst); ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Lilly (Inst); Merrimack (Inst); Millennium (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Celgene; H3 Biomedicine; Incyte; Merck; Prime Oncology; Sanofi; SERVIER